Compare WSR & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSR | TBPH |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 973.9M | 824.9M |
| IPO Year | 2002 | 2013 |
| Metric | WSR | TBPH |
|---|---|---|
| Price | $19.03 | $16.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $19.00 | $18.40 |
| AVG Volume (30 Days) | ★ 436.5K | 289.3K |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | 31.94 | ★ 279.13 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $160,859,000.00 | $15,386,000.00 |
| Revenue This Year | $2.77 | $8.46 |
| Revenue Next Year | $4.21 | N/A |
| P/E Ratio | $237.66 | ★ N/A |
| Revenue Growth | ★ 4.26 | N/A |
| 52 Week Low | $11.43 | $9.98 |
| 52 Week High | $19.02 | $21.03 |
| Indicator | WSR | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 80.32 | 40.51 |
| Support Level | $18.90 | $13.41 |
| Resistance Level | N/A | $17.21 |
| Average True Range (ATR) | 0.02 | 0.34 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 93.75 | 4.84 |
Whitestone REIT is a real estate investment trust (REIT) that owns and operates commercial properties in culturally diverse metropolitan markets. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business-friendly locations in and around Austin, Scottsdale, Dallas, Houston, Phoenix, Arizona, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.